EGFR-Targeted PROX-TEN Dual-Masked T-Cell Engager

Mechanism

Also known as: EGFR-targeted PRO-XTEN® dual-masked TCE

Related News

Vir Biotechnology Reports Q4 2025 Results, Announces Astellas Collaboration on VIR-5500

Feb 24, 2026

Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.

Vir Biotechnology Reports Q4 2025 Results, Announces Astellas Collaboration on VIR-5500

Feb 24, 2026

Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.